ReviewClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2016
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.
Review in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- Timing of Aspirin Use Among Patients With Colorectal Cancer in Relation to Mortality: A Systematic Review and Meta-Analysis.JNCI cancer spectrum · 2021Pooled it
- In-silico personalized protein-protein interaction networks prioritize candidate compounds for glioblastoma.PLoS computational biology · 2026Article
- Screening, Prognostic, and Predictive Molecular Tools for Colorectal Cancer: Recent Advances in the Classical Background.International journal of molecular sciences · 2026Review
- Integrated Genomic and Single-Cell Analysis Reveals Heterogeneity, Prognosis, and Treatment Vulnerability in Urothelial Carcinoma.Human mutation · 2026Article
- Article
- Identification of progression related LncRNAs in colorectal cancer aggressiveness.Scientific reports · 2025Article
- Association between individual Warburg-related proteins and prognosis in colorectal cancer.The journal of pathology. Clinical research · 2025Article
- Sex Difference of Colon Adenoma Pathway and Colorectal Carcinogenesis.The world journal of men's health · 2024Review
- Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy for Refractory Colorectal Liver Metastasis: A Systematic Review.Cureus · 2023Review
- Colorectal cancer risk stratification on histological slides based on survival curves predicted by deep learning.NPJ precision oncology · 2023Article
- Association between adjuvant therapy and survival in colorectal cancer patients according to metabolic Warburg-subtypes.Journal of cancer research and clinical oncology · 2023Article
- Evolution of Resistance to Irinotecan in Cancer Cells Involves Generation of Topoisomerase-Guided Mutations in Non-Coding Genome That Reduce the Chances of DNA Breaks.International journal of molecular sciences · 2023Article
- Review
- Evaluation of CRC-Metastatic Hepatic Lesion Chemoembolization with Irinotecan-Loaded Microspheres, According to the Site of Embolization.Journal of personalized medicine · 2022Article
- Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes.Current oncology (Toronto, Ont.) · 2022Article
- Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry.Targeted oncology · 2022Article
- Phenotype-Genotype Correlation in Colorectal Cancer: A Real-Life Study.GE Portuguese journal of gastroenterology · 2022Article
- Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach.World journal of clinical oncology · 2021Review
- Global colorectal cancer burden in 2020 and projections to 2040.Translational oncology · 2021Review
- A methylation-driven gene panel predicts survival in patients with colon cancer.FEBS open bio · 2021Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Colorectal cancer (CRC) is a disease in which pathogenesis is influenced by genetic and epigenetic events that occur with tumor initiation and progression. Large variation exists in individual patient prognosis and response to chemotherapy, caused by molecular heterogeneity. Certain biomarkers have been identified that can predict clinical outcome beyond tumor staging, and inform treatment selection. Molecular testing is routinely performed in clinical practice for the selection of patients for targeted biological agents or immunotherapy, and is advocated for prognostic stratification. Estimating prognosis can avoid undertreatment or overtreatment and also guide the intensity of patient follow-up. Classifiers of CRC have been developed that integrate genetic and/or epigenetic features. The mutational status of KRAS and BRAF(V600E) oncogenes combined with analysis of the DNA mismatch repair system with/without the CpG island methylator phenotype (CIMP) has been shown to identify colon cancer subtypes with distinct clinical features and prognoses. Gene expression profiling has also been used to subtype CRCs and can overcome the limitations of single/limited gene testing. A recent effort identified 4 consensus molecular subtypes of biological relevance that were associated with different patient outcomes. Efforts to validate and refine these subtypes to include additional genomic features are ongoing. The focus of this article is to highlight molecular markers that can inform clinical decision-making in patients with CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.